Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.10 |
---|---|
High | 10.10 |
Low | 10.00 |
Bid | 10.00 |
Offer | 10.60 |
Previous close | 10.00 |
Average volume | -- |
---|---|
Shares outstanding | 10.79m |
Free float | 8.65m |
P/E (TTM) | -- |
Market cap | 180.78m USD |
EPS (TTM) | -2.16 USD |
Data delayed at least 15 minutes, as of Dec 22 2022.
More ▼
Announcements
- MediWound to Report Third Quarter 2024 Financial Results
- MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
- MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
- MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
- MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
- MediWound to Report Second Quarter 2024 Financial Results
- MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
- MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
More ▼